Studies on the Effect of the Apolipoprotein E Genotype on the Lipid Profile in Alzheimers Disease

Sabbagh, Marwan N.; Sandhu, Shawn; Kolody, Heather; Lahti, Tyson; Silverberg, Nina; Sparks, David L.

doi:10.2174/156720506776383013

Cited by 15 publications

(10 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There have also been reports from three prospective studies assessing the effect of statins on cognitive function in younger individuals at risk of heart disease [1][2][3], and two randomized placebo controlled pilot studies testing a statin for benefit in the treatment of AD [4,5]. In the study testing atorvastatin as a treatment for AD it was shown reduced cholesterol levels occurred in advance of clinical benefit [6], and that greater clinical benefit was identified among those patients harboring the ApoE-4 genotype [7], which is known to increase both the risk of AD and circulating cholesterol levels [8,9].…”

Section: Introductionmentioning

confidence: 99%

Reduced Risk of Incident AD with Elective Statin Use in a Clinical Trial Cohort

Sparks

Kryscio²,

Sabbagh³

et al. 2008

CAR

Self Cite

113

View full text Add to dashboard Cite

Statins have been reported to reduce the risk and be of benefit in the treatment of Alzheimer's disease (AD). Individuals enrolling in the randomized controlled trial testing two anti-inflammatory agents for primary prevention of AD (Alzheimer's Disease Anti-inflammatory Prevention Trial; ADAPT) were allowed the elective use of statins. Our objective was to assess whether statin use is associated with reduced risk of incident AD among ADAPT participants. In primary ADAPT study , participants were assessed annually for cholesterol levels and cognitive status. If impairment in cognition was noted, a dementia evaluation was performed. Onset of mild cognitive impairment (MCI) or AD was taken as the date of this evaluation. Time-to-onset was analyzed in six-month intervals following enrollment. Without knowledge of primary treatment assignment in ADAPT, participants were grouped by their self-reported use of lipid-lowering agents (LLA). In the current ancillary ADAPT study we found that elective statin use was associated with significantly reduced risk of incident AD after adjustment for age, gender, education and Apolipoprotein E (ApoE) genotype. The findings were similar when comparing all LLA use (statin and non-statin LLA) to non-LLA use. Cholesterol levels were lower among statin users compared with non-LLA users, but the MMSE scores were equivalent. The data suggest that statin therapy may be of benefit in reducing the risk of AD.

show abstract

Section: Introductionmentioning

confidence: 99%

Reduced Risk of Incident AD with Elective Statin Use in a Clinical Trial Cohort

Sparks

Kryscio²,

Sabbagh³

et al. 2008

CAR

Self Cite

113

View full text Add to dashboard Cite

show abstract

“…However, no significant differences were noted in total cholesterol, HDL, total cholesterol to HDL ratio or triglyceride levels 17 . ApoE4 heterozygotes were also noted to have higher HDL levels and lower total cholesterol to HDL ratios when compared to ApoE4 homozygotes.…”

Section: 5 Discussionmentioning

confidence: 69%

“…Past studies have shown that ApoE4 carriers have significantly greater mean LDL when compared to ApoE4 negative individuals 17 . However, no significant differences were noted in total cholesterol, HDL, total cholesterol to HDL ratio or triglyceride levels 17 .…”

Section: 5 Discussionmentioning

confidence: 99%

The effect of statins on rate of cognitive decline in mild cognitive impairment

Smith

Kang

Sabbagh

et al. 2017

A&D Transl Res & Clin Interv

View full text Add to dashboard Cite

IntroductionThis study's aims are to identify whether a relationship between statin use and rate of cognitive decline exists. The relationship between statins and mild cognitive impairment (MCI) has been investigated in the past with the evidence showing mixed results.MethodsSeven hundred sixty-eight subjects were identified with MCI. Subjects were stratified into six possible groups according to apolipoprotein E (APOE) ε4 allele status and statin use and assessed for decline in cognitive function.ResultsAll cognitive assessments trended toward less decline with statin use. Alzheimer’s Disease Assessment Scale 11 (ADAS 11) showed the biggest difference in mean change between statin users and nonusers (−0.82 vs. −1.22, respectively). Change reached marginal significance on the ADAS 11 when stratified by APOE ε4–negative subjects.DiscussionAll cognitive assessments trended toward less decline when subjects were concurrently treated with a statin, supporting the position that statins do not have a net negative effect on cognitive assessment and suggesting a potential treatment benefit.

show abstract

“…Past studies have shown that APOE ε4 carriers have significantly greater mean LDL compared with APOE ε4-negative individuals [17]. However, no significant differences were noted in total cholesterol, HDL, total cholesterol to HDL ratio, or triglyceride levels [17].…”

Section: Discussionmentioning

confidence: 98%

P2‐028: The Effect of Statins on Rate of Cognitive Decline in Mild Cognitive Impairment

Smith

Kang

Sabbagh

2016

Alzheimer's & Dementia

View full text Add to dashboard Cite

Introduction: This study's aims are to identify whether a relationship between statin use and rate of cognitive decline exists. The relationship between statins and mild cognitive impairment (MCI) has been investigated in the past with the evidence showing mixed results. Methods: Seven hundred sixty-eight subjects were identified with MCI. Subjects were stratified into six possible groups according to apolipoprotein E (APOE) ε4 allele status and statin use and assessed for decline in cognitive function.Results: All cognitive assessments trended toward less decline with statin use. Alzheimer's Disease Assessment Scale 11 (ADAS 11) showed the biggest difference in mean change between statin users and nonusers (20.82 vs. 21.22, respectively). Change reached marginal significance on the ADAS 11 when stratified by APOE ε4-negative subjects. Discussion: All cognitive assessments trended toward less decline when subjects were concurrently treated with a statin, supporting the position that statins do not have a net negative effect on cognitive assessment and suggesting a potential treatment benefit.

show abstract

Studies on the Effect of the Apolipoprotein E Genotype on the Lipid Profile in Alzheimers Disease

Abstract: ApoE gene status has minimal influence on the lipid panel or mean age in AD. Apo E gene dose does influence the lipid panel with Apo E 2/2, and 2/3 having significantly better lipid panels and older age of onset.

Cited by 15 publications

References 24 publications

Reduced Risk of Incident AD with Elective Statin Use in a Clinical Trial Cohort

Reduced Risk of Incident AD with Elective Statin Use in a Clinical Trial Cohort

The effect of statins on rate of cognitive decline in mild cognitive impairment

P2‐028: The Effect of Statins on Rate of Cognitive Decline in Mild Cognitive Impairment

Contact Info

Product

Resources

About